Acris Antibodies

Acris Antibodies specializes in the development and production of high-quality antibodies and related reagents for research in molecular biology and biotechnology, serving a diverse, global clientele. Founded in 1998 in Herford, Germany, Acris Antibodies focuses on the production of antibodies and biological reagents. In October 2015, Acris was acquired by OriGene Technologies, a portfolio company of multiple investors including IDG Capital Partners and Kleiner Perkins Caufield & Byers. The firm has completed one deal to date.

The company is known for its expertise in serving academic institutions and research laboratories. Acris Antibodies offers a wide range of biological reagents and tools designed for molecular biology and biotechnology research. The product portfolio includes antibodies, proteins, and gene expression products intended for various applications such as immunoassays and Western blotting. The primary customers include academic institutions, pharmaceutical companies, and biotechnology firms engaged in drug development and disease research.

Acris Antibodies generates revenue through direct sales to a varied customer base that comprises academic institutions, research hospitals, and private laboratories. Their B2B sales model requires clients to place orders through email, fax, or telephone, fostering ongoing relationships with the sales team. The pricing structures are based on specific reagents ordered, with a particular emphasis on monoclonal and polyclonal antibodies, which are popular in the market. Future growth at Acris Antibodies will focus on designing new products and expanding its market reach.

The company seeks to introduce innovative antibody products tailored to emerging research needs by the end of 2023. Additionally, plans are in place to penetrate new geographic markets in Asia and North America, targeting these regions for expansion by 2025. The acquisition by OriGene Technologies in October 2015 has provided strategic support for these initiatives, with an undisclosed financial backing aiding in product development and market entry efforts.